Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Anticoagulation with direct-acting oral anticoagulants (DOACs) is recommended over
warfarin for stroke prevention in patients with atrial fibrillation (AF). The efficacy of DOACs …

Background Limited clinical data exist describing the use of direct oral anticoagulants
(DOACs) in patient with extreme body weight. Thus, the International Society of Thrombosis …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

Background: It is unclear whether the overall effectiveness and safety of direct oral
anticoagulants (DOACs) are consistent in patients with nonvalvular atrial fibrillation (AF) and …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

Objectives Current evidence indicates that the pharmacokinetic profile of rivaroxaban is not
significantly impacted by body weight. However, real-world data are needed to better assess …

Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …

Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

Direct oral anticoagulants (DOACs) are a favored treatment to prevent stroke in patients with
atrial fibrillation (AF). There are limited data concerning the efficacy and safety of DOACs in …